Log in

Epizyme Stock Price, News & Analysis (NASDAQ:EPZM)

$10.03
+0.05 (+0.50 %)
(As of 10/13/2019 04:00 PM ET)
Today's Range
$9.98
Now: $10.03
$10.31
50-Day Range
$9.85
MA: $11.72
$13.43
52-Week Range
$5.14
Now: $10.03
$16.59
Volume814,667 shs
Average Volume760,812 shs
Market Capitalization$913.13 million
P/E RatioN/A
Dividend YieldN/A
Beta2.37
Epizyme, Inc, a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EPZM
CUSIPN/A
Phone617-229-5872

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$21.70 million
Book Value$2.94 per share

Profitability

Net Income$-123,630,000.00

Miscellaneous

Employees124
Market Cap$913.13 million
Next Earnings Date11/1/2019 (Estimated)
OptionableOptionable

Receive EPZM News and Ratings via Email

Sign-up to receive the latest news and ratings for EPZM and its competitors with MarketBeat's FREE daily newsletter.


Epizyme (NASDAQ:EPZM) Frequently Asked Questions

What is Epizyme's stock symbol?

Epizyme trades on the NASDAQ under the ticker symbol "EPZM."

How were Epizyme's earnings last quarter?

Epizyme Inc (NASDAQ:EPZM) released its quarterly earnings results on Friday, August, 9th. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by $0.02. The biopharmaceutical company had revenue of $5.90 million for the quarter, compared to analyst estimates of $0.32 million. The company's quarterly revenue was down 50.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.42) EPS. View Epizyme's Earnings History.

When is Epizyme's next earnings date?

Epizyme is scheduled to release their next quarterly earnings announcement on Friday, November 1st 2019. View Earnings Estimates for Epizyme.

What price target have analysts set for EPZM?

8 Wall Street analysts have issued 1 year target prices for Epizyme's stock. Their predictions range from $11.00 to $25.00. On average, they expect Epizyme's stock price to reach $17.57 in the next twelve months. This suggests a possible upside of 75.2% from the stock's current price. View Analyst Price Targets for Epizyme.

What is the consensus analysts' recommendation for Epizyme?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Epizyme in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Epizyme.

Has Epizyme been receiving favorable news coverage?

Media stories about EPZM stock have trended negative recently, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Epizyme earned a coverage optimism score of -2.6 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for Epizyme.

Are investors shorting Epizyme?

Epizyme saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 8,340,000 shares, an increase of 5.3% from the August 30th total of 7,920,000 shares. Based on an average daily volume of 653,500 shares, the days-to-cover ratio is currently 12.8 days. Currently, 10.9% of the company's stock are short sold. View Epizyme's Current Options Chain.

Who are some of Epizyme's key competitors?

What other stocks do shareholders of Epizyme own?

Who are Epizyme's key executives?

Epizyme's management team includes the folowing people:
  • Mr. Robert B. Bazemore Jr., Pres, CEO, Sec. & Director (Age 51)
  • Mr. Matthew E. Ros, Chief Strategy & Bus. Officer and Principal Financial Officer (Age 52)
  • Dr. H. Robert Horvitz, Co-Founder & Chairman of the Scientific Advisory Board
  • Dr. Yi Zhang, Scientific Co-Founder & Member of The Scientific Advisory Board
  • Mr. Joseph Beaulieu, Controller, Treasurer & Principal Accounting Officer (Age 38)

How do I buy shares of Epizyme?

Shares of EPZM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Epizyme's stock price today?

One share of EPZM stock can currently be purchased for approximately $10.03.

How big of a company is Epizyme?

Epizyme has a market capitalization of $913.13 million and generates $21.70 million in revenue each year. The biopharmaceutical company earns $-123,630,000.00 in net income (profit) each year or ($1.72) on an earnings per share basis. Epizyme employs 124 workers across the globe.View Additional Information About Epizyme.

What is Epizyme's official website?

The official website for Epizyme is http://www.epizyme.com/.

How can I contact Epizyme?

Epizyme's mailing address is 400 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-229-5872 or via email at [email protected]


MarketBeat Community Rating for Epizyme (NASDAQ EPZM)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  417 (Vote Outperform)
Underperform Votes:  318 (Vote Underperform)
Total Votes:  735
MarketBeat's community ratings are surveys of what our community members think about Epizyme and other stocks. Vote "Outperform" if you believe EPZM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EPZM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/13/2019 by MarketBeat.com Staff

Featured Article: What does EPS mean?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel